Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EBL-1463
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : CARB-X
Deal Size : $5.8 million
Deal Type : Funding
Details : Mutabilis’ new intravenous drug, EBL-1463, is a novel class of non-beta-lactam inhibitor of penicillin binding proteins (PBPs) called dabocins. Mutabilis’ new drug aims to treat deadly ‘nightmare bacteria’ infections safely and effectively.
Brand Name : EBL-1463
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 03, 2021
Lead Product(s) : EBL-1463
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : CARB-X
Deal Size : $5.8 million
Deal Type : Funding
Lead Product(s) : 2G-Dabocins
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Organovo Holdings
Deal Size : $11.9 million
Deal Type : Financing
Details : This investment will allow the Mutabilis to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimization.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
January 06, 2020
Lead Product(s) : 2G-Dabocins
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Organovo Holdings
Deal Size : $11.9 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?
Reset All
